iBio (IBIO) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBIO iBio Inc IBIO
32 GF Score
Price $1.44
GF Value $0.05
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iBio Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IBIO
32GF Score
iBio Inc IBIO
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is iBio (IBIO) Overvalued in 2026?

Based on GuruFocus' analysis, iBio stock appears to be overvalued. The current stock price of $1.44 is trading 2770% above its estimated GF Value™ of $0.05. GuruFocus considers iBio to be Significantly Overvalued.

Key valuation signals for IBIO:

  • Short Ratio:
  • GF Value™: $0.05 vs. price of $1.44 (2770% above fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iBio Business Description

Other Exchanges 0JV0:Germany
Address 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
32GF Score

Get the complete analysis for IBIO

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.05
GF Value